The Europe xenotransplantation market size was surpassed at USD 850 million in 2025 and is predicted to reach around USD 2,068.33 million by 2035, expanding at a CAGR of 9.30% from 2026 to 2035. Advancements in multiplex gene editing and CRISPR gene editing, and regulatory frameworks by the European regulatory bodies are gaining traction in Europe.

Europe Xenotransplantation Market Statical Scope

The National Xenotransplantation Plan is a strategic initiative aiming to establish a dedicated French framework to eliminate legal, industrial, and ethical barriers. European agencies are making efforts to build a scientific framework for animal-to-human organ transplantation.

The European Union is also committed to boosting legislative mandates and strategic procurement programs to prepare member states for clinical translation. The Substances of Human Origin Regulation is a framework that governs tissues, blood, and cells across the European Union.

Europe Xenotransplantation Market Share, By Type, 2025 (%)

• Transplant Diagnostics- The transplant diagnostics segment dominated the market in 2025, with a share of 41%, owing to the primary industry developments like the U.S. FDA investigational new drug approvals and strategic biotech alliances. The regulated trials mandate ultra-high resolution screening protocols.
• Organ Preservation Solutions- The organ preservation solutions segment held a 34% share and is expected to grow in the coming years, driven by the preclinical and clinical trial pipeline and expanded clinical infrastructure. A precise ex vivo chemical environment is required for genetically modified organs.
• Tissue Products- The tissue products segment held a 25% share and is expected to grow in the upcoming period due to a shift from experimental validation to early commercialization and first-in-human clinical trials . There is a high demand for advanced multi-gene CRISPR editing and decellularization platforms.

Europe Xenotransplantation Market Share, By Application, 2025 (%)

• Kidney - The kidney segment dominated the market in 2025, with a share of 44%, supported by innovative immunosuppressive regimens and CRISPR-Cas9 gene editing. The leading biotechnology companies and research centers received approvals for human trials by the U.S. Food and Drug Administration (FDA).
• Heart - The heart segment held a 38% share and is expected to grow in the coming years, driven by an unlimited supply of organs through xenotransplantation, which prevents patients with end-stage heart failure. Advanced genetic engineering options overcome immune rejection, allow researchers to insert human transgenes, and result in controlled organ growth.
• Other Organs - The other organs segment held a 18% share and is expected to grow in the upcoming period due to customized multi-gene editing and costimulation blockade drugs.

Recent Developments in the Europe Xenotransplantation Market

• In June 2025, Makana Therapeutics announced its discovery in pig-to-human transplantation. Makana planned to launch a pre-clinical study in 2025 and expects to conduct a first-in-human clinical trial in kidney xenotransplantation in early 2026 after approval by the U.S. FDA.

Competitive Landscape

The leading European research and clinical initiatives are taken by the Munich Group and Hannover Medical School in Germany, and OrganOX Limited in the UK. Europe remains the primary hub for the development of ethical policy, clinical trials, and organ preservation technology. The prominent industrial offerings include multi-gene edited pig organs, porcine islet cell transplants, ex vivo machine perfusion systems, and corneal xenografts. The Munich Group in Europe focuses on multi-organ and cardiac xenografts.

Segments Covered in the Report

By Type

• Organ Preservation Solutions
• Transplant Diagnostics
• Tissue Products

By Application

• Heart
• Kidney
• Other Organs